-$0.25 (-0.3%)
Closing price October 26, 2020
Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
Tuesday's top analyst upgrades, downgrades and initiations included Aurora Cannabis, Biogen, EverQuote, Micron Technology, Nio, Nvidia, Palo Alto Networks, Tandem Diabetes Care, Tesla and
24/7 Wall St. screened the Merrill Lynch health care research database looking for large pharmaceutical leaders that also pay solid and dependable dividends. These five make sense for growth and...
Medicines Co shares shot up on Monday after it was reported that Novartis will be acquiring the firm. The transaction was unanimously approved by the boards of directors of both companies.
Medicines shares shot up on Tuesday after it was reported that Novartis might be eyeing this company as its newest acquisition.
The top analyst upgrades, downgrades and initiations seen on Wednesday included DowDuPont, Electronic Arts, Estee Lauder, Exxon, Generac, Match, Nasdaq, Novartis, PayPal, Snap and Vishay.
Tilray shares made a solid gain on Tuesday after the company announced that it entered a global agreement to collaborate with Sandoz, a subsidiary of Novartis.
  Stocks were indicated to open lower on Monday after weekend news that sounds like a China trade deal is not on the way very soon. Investors have been forced to see numerous waves of selling in...
Endocyte shares were up sharply early Thursday after it was announced that the company would be acquired.
The founders of Instagram leave the company, Novartis to cut hundreds of jobs, crude oil prices jump above $80 a barrel, and other important business headlines.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Baker Hughes, CBS, Generac, Halliburton, Nike, PG&E, Snap, Tesla, Weatherford and Western Digital.
2018 has been a strange time for investors. While the U.S. stock market sits close to all-time highs, many of the emerging and other developed markets nations have seen their shares take a beating....
The topic of acceptable costs versus acceptable results is one that may never have a final conclusion in which everyone agrees.
Adamis Pharmaceuticals saw its shares shoot up early on Monday after the firm announced a partnership with a subsidiary of Novartis.